Teratogenicity of carbamazepine-10,11-epoxide and oxcarbazepine in the SWV mouse

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1237-1242

  Bennett, Greg D ^a   Amore, Benny M ^b   Finnell, Richard H ^a   Wlodarczyk, B ^a   Kalhorn, Thomas F ^b   Skiles, Gary L ^b   Nelson, Sidney D ^b   Slattery, John T ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE 10,11 OXIDE; OXCARBAZEPINE; PHENOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEEDING; FEMALE; MOUSE; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; TERATOGENICITY;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; FEMALE; MICE; MICE, INBRED STRAINS; PREGNANCY; TERATOGENS;

EID: 0030426706     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ALBANI, F., THEODORE, W. H., WASHINGTON, P., DEVINSKY, O., BROMFIELD, E., PORTER, R. J. AND NICE, F. J.: Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 32: 130-132, 1991.
2. ANDERMANN, E.: Pregnancy and oxcarbazepine. Epilepsia 35: suppl. 3, S26, 1994.
3. BAKER, K. M., FRIGERIO, A., MORSELLI, P. L. AND PIFFERI, G.: Identification of a rearranged degradation product from carbamazepine-10,11-epoxide. J. Pharm. Sci. 62: 475-476, 1973.
4. BARROW, M. W. AND TAYLOR, J. P.: A rapid method for detecting malformations in rat fetuses. J. Morphol. 127: 291-306, 1969.
5. BEYER, K. H. AND SPITELLER, G.: A new carbamazepine metabolite in uraemic filtrate. Xenobiotica 22: 1029-1035, 1992.
6. BÜLAU, P., PAAR, W. D. AND VON UNRUH, G. E.: Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur. J. Clin. Pharmacol. 34: 311-313, 1988.
7. CHEMICAL ABSTRACTS: 10-Oxo-10,11-dihydro-5H-dibenz[b, f]azepine-5-carboxamide (Abstract no. 128762s). Chem. Abstr. 92: 686, 1980.
8. CRARY, D. D.: Modified benzyl alcohol clearing of alizarin stained specimens without loss of flexiblity. Stain Technol. 37: 124-125, 1962.
9. DANSKY, L. V. ANE FINNELL, R. H.: Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiological and experimental findings spanning three decades. II. Human studies. Reprod. Toxicol. 5: 301-335, 1991.
10. DAM, M., EKBERG, R., LOYNING, Y., WALTIMO, O. AND JAKOBSEN, K.: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3: 70-76, 1989.
11. EICHELBAUM, M., TOMSON, T., TYBING, G. AND BERTILSSON, L.: Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin. Pharmacokinet. 10: 80-90, 1985.
12. EL-SAYED, M. G. A., ALY, A. E., KADRI, M. AND MOUSTAFA, A. M.: Comparative study on the teratogenicity of some antiepiletics in the rat. East Afr. Med. J. 60: 407-415, 1983.
13. ELUMA, F. O., SUCHESTON, M. E., HAYES, T. G. AND PAULSON, R. B.: Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus. J. Craniofacial Genet. Dev. Biol. 4: 191-210, 1984.
14. FAIGLE, J. W. AND FELDMANN, K. F.: Carbamazepine. Chemistry and Biotransformation. In Antiepileptic Drugs, ed. by R. H. Levy, R. H. Mattson and B. S. Meldrum, pp. 499-513, Raven Press Ltd., New York, 1995.
15. FELDMANN, K. F., BRECHBÜHLER, S., FAIGLE, J. W. AND IMHOF, P.: Pharmacokinetics and metabolism of GP 47 680, a compound related to carbmazepine, in animals and man. In Advances in Epileptology, ed. by H. Meinardi and A. J. Rowan, pp. 290-294. Swets & Zeitlinger B. V., Amsterdam, 1977.
16. FINNELL, R. H., MOHI, V. K., BENNETT, G. D. AND TAYLOR, S. M.: Failure of epoxide formation to influence carbamazepine-induced teratogenesis in a mouse model. Teratogen. Carcinogen. Mutagen. 6: 393-401, 1986.
17. FINNELL, R. H., BENNEIT, G. D., SLATTERY, J. T., AMORE, B. M., BAJPAI, M. AND LEVY, R. H.: Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology 52: 324-332, 1995.
18. FRIGERIO, A., FANELLI, R., BIANDRATE, P., PASSERINI, G., MORSELLI, P. L. AND GARATTINI, S.: Mass spectrometric characterization of carbamazepine-10,11-epoxide, a carbamazepine metabolite isolated from human urine. J. Pharm. Sci. 61: 1144-1147, 1972.
19. FRIIS, M. L., KRISTENSEN, O., BOAS, J., DALBY, M., DETH, S. H., GRAM, L., MIKKELSEN, M., PEDERSEN, B., SABERS, A., WORM-PETERSON, J., ANDERSEN, D. AND JENSEN, P. K.: Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol. Scand. 87: 224-227, 1993.
20. HOUTKOOPER, M. A., LAMMERTSMA, A., MEYER, J. W. A., GOEDHART, D. M., MEINARDI, H., VAN OORSCHOT, C. A. E. H., BLOM, G. F., HÖPPENER, R. J. E. A. AND HULSMAN, F A. R. J.: Oxcarbazepine (GP 47 680): A possible alternative to carbamazepine? Epilepsia 28: 693-698, 1987.
21. JONES, K. L., LARCO, R. V., JOHNSON, K. A. AND ADAMS, J.: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 320: 1661-1666, 1989.
22. KANEKO, S., OTANI, K., FUKUSHIMA, Y., OGAWA, Y., NOMURA, Y., ONO, T., MAKANE, Y., TERANISHI, T. AND GOTO, M.: Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 29: 459-467, 1988.
23. KANEKO, S., OTANI, K., KONDO, T., FUKUSHIMA, Y., NAKAMURA, Y., OGAWA, Y., KAN, R., TAKEDA, A., NAKANE, Y. AND TERANISHI, T.: Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 42: suppl. 5, 68-74, 1992.
24. KERR, B. M., MARTINEZ-LAGE, J. M., VITERI, C., TOR, J., EDDY, A. C. AND LEVY, R. H.: Carbamzepine dose requirements during stiripentol therapy: Influence of cytochrome P450 inhibition by stiripentol. Epilepsia 32: 267-274, 1991.
25. KERR, B. M. AND LEVY, R. H.: Inhibition of epoxide hydrolase by anticonvulsants and risk of teratogenicity. Lancet i: 610-611, 1989.
26. KERR, B. M. AND LEVY, R. H.: Carbamazepine. Carbamzepine Epoxide. In Antiepileptic Drugs, ed. by R. H. Levy, R. H. Mattson and B. S. Meldrum, pp. 529-541, Raven Press Ltd., New York, 1995.
27. KUMPS, A. AND WURTH, C.: Oxcarbazepine disposition: Preliminary observations in patients. Biopharm. Drug Dispos. 11: 365-370, 1990.
28. LERTRATANANGKOON, K. AND HORNING, M. G.: Metabolism of carbamazepine. Drug Metab. Dispos. 10: 1-10, 1982,
29. LILLIBRIDGE, J. L., AMORE, B. M., SLATTERY, J. T., KALHORN, T. F., NELSON, S. D., FINNELL, R. H. AND BENNETT, G. D.: Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab. Dispos. 24: 509-514, 1996.
30. LINDHOUT, D., HOPPENER, R. J. E. A. AND MEINARDI, H.: Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation of carbamazepine. Epilepsia 25: 77-83, 1984.
31. MCKEE, P. J. W., BLACKLAW, J., BUTLER, E., GILLHAM, R. A. AND BRODIE, M. J.: Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res. 11: 192-198, 1992.
32. MADDEN, S., MAGGS, J. L. AND PARK, B. K.: Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab. Dispos. 24: 469-479, 1996.
33. NAKANE, Y., OKUMA, T., TAKAHASHI, R., SATO, Y., WADA, T., SATO, T., FUKUSHIMA, Y., KUMASHIRO, H., ONO, T., TAKAHASHI, T., AOKI, Y., KAZAMATSURI, H., INAMI, H., KOMAI, S., SEINO, M., MIYAKOSHI, M., TANIMURA, T., HAZAMA, H., KAWAHARA, R., OTSUKI, S., HOSOKAWA, K., INANAGA, K., NAKAZAWA, Y. AND YAMAMOTO, K.: Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: Report of a collaborative study group in Japan. Epilepsia 21: 663-680, 1980.
34. OMTZIGT, J. G. C., LOS, F. J., MEIJER, J. W. A. AND LINDHOUT, D.: The 10,11-Epoxide-10,11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy. Ther. Drug Monit. 16: 1-10, 1993.
35. PAULSON, R. B., PAULSON, G. W. AND JREISSATY, S.: Phenytoin and carbamazepine in production of cleft palates in mice: comparision of teratogenic effects. Arch. Neurol. 36: 823-836, 1979.
36. PIENIMÄKI, P., HARTIKAINEN, A.-L., ARVELA, P., PARTANEN, T., HERVA, R., PELKONEN, O. AND VÄHÄKANGAS, K.: Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 36: 241-248, 1995.
37. RAMBECK, B., SALKE-TREUMANN, A., MAY, T. AND BOENIGK, H. E.: Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents. Eur. Neurol. 30: 79-83, 1990.
38. ROSA F. W.: Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 324: 674-677, 1991.
39. 14C-oxcarbazepine in man. Xenobiotica 16: 769-778, 1986.
40. SNELL, G. D., FEKETE, E. AND HUMMEL, K. P.: The relation of mating, ovulation, and the estrus smear inthe house mouse to the time of day. Anat. Rec. 76: 30-54, 1948.
41. SOKAL, R. R. AND ROHLF, F. J.: Biometry: The Principles and Practice of Statistics in Biological Research, W. H. Freeman, San Francisco, 1981.
42. SULLIVAN, F. M. AND MCELHATTON, P., R.: A comparison of the teratogenic activity of the antiepiletic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice. Toxicol. Appl. Pharmacol. 40: 365-378, 1977.
43. VORHEES, C. V., ACUFF, K. D., WEISENBURGER, W. P. AND MINCK, D. R.: Teratogenicity of carbamazepine in rats. Teratology 41: 311-317, 1990.